Literature DB >> 19635582

Subcutaneous boosting with heparin binding haemagglutinin increases BCG-induced protection against tuberculosis.

Carine Rouanet1, Anne-Sophie Debrie, Sophie Lecher, Camille Locht.   

Abstract

Pulmonary tuberculosis remains a major health problem. Effective vaccination strategies are urgently needed. It was previously demonstrated that purified Mycobacterium bovis BCG Heparin Binding Haemagglutinin (HBHA) is able to induce in BALB/c mice protection levels against a Mycobacterium tuberculosis infection that are similar to those offered by BCG. Here we developed a heterologous prime/boost immunisation approach using a combination of BCG and HBHA in order to increase the protective immune response. We show that the time period between BCG priming and HBHA boosting strongly influences the efficacy of the boost. The optimized vaccine protocol consisting of a BCG administration followed 8 months later by boosting with HBHA resulted in an increase in the level of protection of up to 0.7log when compared to BCG alone. These results suggest an immunisation strategy where BCG is administered to neonates and is followed by subcutaneous HBHA boosting in young adults.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19635582     DOI: 10.1016/j.micinf.2009.07.005

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  19 in total

1.  Mucosal vaccination against tuberculosis using inert bioparticles.

Authors:  Rajko Reljic; Laura Sibley; Jen-Min Huang; Ilaria Pepponi; Andreas Hoppe; Huynh A Hong; Simon M Cutting
Journal:  Infect Immun       Date:  2013-08-19       Impact factor: 3.441

2.  Pyoderma gangrenosum-like skin changes after subcutaneous administration of low molecular weight heparin.

Authors:  Małgorzata Sobieszczańska; Sławomir Tubek; Ilona Kura
Journal:  Hum Vaccin Immunother       Date:  2014-01-17       Impact factor: 3.452

3.  A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis.

Authors:  Sylvie Bertholet; Gregory C Ireton; Diane J Ordway; Hillarie Plessner Windish; Samuel O Pine; Maria Kahn; Tony Phan; Ian M Orme; Thomas S Vedvick; Susan L Baldwin; Rhea N Coler; Steven G Reed
Journal:  Sci Transl Med       Date:  2010-10-13       Impact factor: 17.956

4.  Host cell-induced components of the sulfate assimilation pathway are major protective antigens of Mycobacterium tuberculosis.

Authors:  Rachel Pinto; Lisa Leotta; Erin R Shanahan; Nicholas P West; Thomas S Leyh; Warwick Britton; James A Triccas
Journal:  J Infect Dis       Date:  2012-12-07       Impact factor: 5.226

5.  Influence of maternal gestational treatment with mycobacterial antigens on postnatal immunity in an experimental murine model.

Authors:  Muhammad Jubayer Rahman; Irene Roman Dégano; Mahavir Singh; Carmen Fernández
Journal:  PLoS One       Date:  2010-03-15       Impact factor: 3.240

6.  Comparison of BCG prime-DNA booster and rBCG regimens for protection against tuberculosis.

Authors:  Kun Tan; Jinping Liang; Xindong Teng; Xiaochun Wang; Jingyan Zhang; Xuefeng Yuan; Xionglin Fan
Journal:  Hum Vaccin Immunother       Date:  2013-11-05       Impact factor: 3.452

7.  IL-28B down-regulates regulatory T cells but does not improve the protective immunity following tuberculosis subunit vaccine immunization.

Authors:  Yanping Luo; Xingming Ma; Xun Liu; Xiaoling Lu; Hongxia Niu; Hongjuan Yu; Chunxiang Bai; Jinxiu Peng; Qiaoyang Xian; Yong Wang; Bingdong Zhu
Journal:  Int Immunol       Date:  2015-10-31       Impact factor: 4.823

Review 8.  Prime-boost approaches to tuberculosis vaccine development.

Authors:  Neha Dalmia; Alistair J Ramsay
Journal:  Expert Rev Vaccines       Date:  2012-10       Impact factor: 5.217

9.  Differential contribution of the repeats to heparin binding of HBHA, a major adhesin of Mycobacterium tuberculosis.

Authors:  Pierre Lebrun; Dominique Raze; Bernd Fritzinger; Jean-Michel Wieruszeski; Franck Biet; Alexander Dose; Mathieu Carpentier; Dirk Schwarzer; Fabrice Allain; Guy Lippens; Camille Locht
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

10.  Risk stratification of latent tuberculosis defined by combined interferon gamma release assays.

Authors:  Véronique Corbière; Gaelle Pottier; Florence Bonkain; Kinda Schepers; Virginie Verscheure; Sophie Lecher; T Mark Doherty; Camille Locht; Françoise Mascart
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.